Utility of Preoperative Inflammatory Markers to Distinguish Epithelial Ovarian Cancer from Benign Ovarian Masses

Li, Lian; Tian, Jing; Zhang, Liwen; Liu, Luyang; Sheng, Chao; Huang, Yubei; Zheng, Hong; Song, Fengju; Chen, Kexin

doi:10.7150/jca.51642



International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

Global reach, higher impact

Full Text | PDF

J Cancer 2021; 12(9):2687-2693. doi:10.7150/jca.51642 This issue Cite

Research Paper

Utility of Preoperative Inflammatory Markers to Distinguish Epithelial Ovarian Cancer from Benign Ovarian Masses

Lian Li^1*, Jing Tian^1,2*, Liwen Zhang^1*, Luyang Liu¹, Chao Sheng¹, Yubei Huang¹, Hong Zheng¹, Fengju Song¹, Kexin Chen^1✉

1. Department of Epidemiology and Biostatistics, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
2. Department of Urology, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
* These authors contributed equally to this work.

Citation:

Li L, Tian J, Zhang L, Liu L, Sheng C, Huang Y, Zheng H, Song F, Chen K. Utility of Preoperative Inflammatory Markers to Distinguish Epithelial Ovarian Cancer from Benign Ovarian Masses. J Cancer 2021; 12(9):2687-2693. doi:10.7150/jca.51642. https://www.jcancer.org/v12p2687.htm

Other styles

Abstract

Background: Inflammatory markers have been reported to be predictors for the presence of epithelial ovarian cancer (EOC), however, the cut-off value of each marker remains unclear and predictive capability of the markers in different histology types of EOC is still unknown.

Methods: A total of 207 patients with benign ovarian masses and 887 EOC patients who underwent surgical resection, and were pathologically diagnosed were included. We compared the difference of preoperative inflammatory markers between benign ovarian masses and EOC patients. Stratified analysis by histology subtype was further conducted. Logistic regression analyses and receiver operating characteristic (ROC) curves was used to evaluate the predictive capability of the markers.

Results: Neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), and lymphocyte-to-monocyte ratio (LMR) were significantly associated with all stages and subtypes of EOC (P<0.001). The optimal cut-off points based on ROC curve analyses for NLR, PLR, and LMR were found to be 2.139 (AUC=0.749, P<0.001), 182.698 (AUC=0.730, P<0.001), and 3.619 (AUC = 0.709, P<0.001), respectively. In low CA125 level patients, high level of NLR and PLR increase the risk of endometrioid EOC, while low level of LMR were significantly associated with an increased risk of serous EOC.

Conclusions: In addition to CA125, NLR, PLR, and LMR could be used as predictors of EOC and preoperative inflammatory markers may be used as a potential biomarker for predicting different histotypes of EOC.

Keywords: Epithelial ovarian cancer, Inflammation biomarkers, Diagnosis, Benign ovarian masses, Cancer biomarkers.

Citation styles

APA

Li, L., Tian, J., Zhang, L., Liu, L., Sheng, C., Huang, Y., Zheng, H., Song, F., Chen, K. (2021). Utility of Preoperative Inflammatory Markers to Distinguish Epithelial Ovarian Cancer from Benign Ovarian Masses. Journal of Cancer, 12(9), 2687-2693. https://doi.org/10.7150/jca.51642.

ACS

Li, L.; Tian, J.; Zhang, L.; Liu, L.; Sheng, C.; Huang, Y.; Zheng, H.; Song, F.; Chen, K. Utility of Preoperative Inflammatory Markers to Distinguish Epithelial Ovarian Cancer from Benign Ovarian Masses. J. Cancer 2021, 12 (9), 2687-2693. DOI: 10.7150/jca.51642.

NLM

CSE

Li L, Tian J, Zhang L, Liu L, Sheng C, Huang Y, Zheng H, Song F, Chen K. 2021. Utility of Preoperative Inflammatory Markers to Distinguish Epithelial Ovarian Cancer from Benign Ovarian Masses. J Cancer. 12(9):2687-2693.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.